|
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage Clinical research trials and Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage. Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage clinical trial. Test subjects typically obtain the finest healthcare available for their Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage  Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
For Condition: Intracranial Hemorrhage,Brain Injury,Brain Hemorrhage
Status: Completed
Sponsor(s): National Institute of Child Health and Human Development (NICHD) ,
Synopsis: This large randomized trial tested whether phenobarbital given to a pregnant woman about to deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to 32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were randomized to phenobarbital or usual care. They were treated until they deliver or the fetus reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos corrected age for neurodevelopmental outcome.
Details: The administration of phenobarbital to pregnant women before delivery has been thought to decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this potential neuroprotective therapy further, we determined the effect of antenatal administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and early death. Women who were 24 to 33 weeks pregnant and who were expected to deliver their infants within 24 hours were randomly assigned to receive either intravenous phenobarbital (10 mg/kg body weight) or placebo, followed by maintenance doses until delivery or 34 wks gestation. Infants less than 34 wks at birth underwent serial cranial ultrasonography to detect the presence of intracranial hemorrhage. The sample size of 1038 pregnancies was based on an intracranial hemorrhage rate of 20 percent in the placebo and less than 12 percent in the phenobarbital group; 90 percent power; a 5 percent two-tailed type 1 error; and an 8 percent noncompliance rate. The twin with the highest grade of intracranial hemorrhage was included. Degree of maternal sedation was evaluated after administration of study drug. Neonatal ultrasound exams were performed at 3-5 days, 10-14 days, and 38-42 wks postmenstrual age; neonatal medications were recorded during the first week of life; treatments, and outcomes were recorded through death, discharge, or 120 days, whichever occurred first. Neurodevelopmental outcome was evaluated at 18-22 months corrected age by certified examiners masked to treatment status.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Admission to a high risk perinatal unit or labor and delivery unit; - 24 to 32 completed weeks gestation; - Expected delivery within 24 hrs; - Preterm labor or no labor with planned delivery for maternal-fetal indications; Exclusion Criteria: - Multiple gestation beyond twins
Total Enrollment: 1038
Location and Contact Information:
Overall Study Official:
SeethaShankaran, Principal Investigator, Wayne State University
Additional Information:
Study ID Numbers: NICHD-1000;
Study Start Date: January 1993
Record last reviewed: January 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00009620
Other Brain Hemorrhage Studies:
1. Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
Related Studies:
Other Brain Hemorrhage Clinical Trials
Other Clinical Trials
Other Clinical Trials
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
|
|
|
|
|
|
|
|
